Skip to main content

Main menu

  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us

Clinical Medicine Journal

  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

User menu

  • Log in

Search

  • Advanced search
RCP Journals
Home
  • Log in
  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us
Advanced

Clinical Medicine Journal

clinmedicine Logo
  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

Drug-induced bradycardia

Devamsh GN, Mallikarjun Patil and Syed Shafiq
Download PDF
DOI: https://doi.org/10.7861/clinmed.2022-0431
Clin Med March 2023
Devamsh GN
ASt John's Medical College Hospital, Bengaluru, India
Roles: senior resident
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: devamsh.gn@gmail.com
Mallikarjun Patil
BSt John's Medical College Hospital, Bengaluru, India
Roles: professor and head of the department of medical gastroenterology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Syed Shafiq
CSt John's Medical College Hospital, Bengaluru, India
Roles: associate professor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

A 45-year-old woman presented to the hospital with bloody diarrhoea and significant weight loss over the past 1 month. On admission and evaluation, she was found to have acute ulcerative colitis. She was started on prednisolone and mesalamine therapy. Within 24 hours of initiation of this therapy, the patient complained of giddiness and chest discomfort and was found to have sinus bradycardia on ECG with no acute coronary event. After withdrawing mesalamine, her heart rate normalised within 24 hours and she remained symptom-free. This is a rare case report of severe symptomatic sinus bradycardia due to mesalamine therapy; to our knowledge, only four cases of mesalamine-induced bradycardia have been reported in the literature.

KEYWORDS:
  • mesalamine
  • ulcerative colitis
  • drug side effects
  • bradycardia

Introduction

Drug-induced bradycardia is a common side effect of several medications. Fortunately, symptomatic bradycardia caused by drugs is often reversible by simply withdrawing the culprit drug. The usual culprits are cardiac medications like calcium channel blockers, beta blockers, and other antiarrhythmics which cause bradycardia through known mechanisms affecting the cardiac electrical activity. Other non-cardiac drugs, such as phenytoin, tricyclic antidepressants and lithium, can also cause bradycardia. Sulfasalazine, the parent compound of all amino salicylates (ASAs), is used in the management of inflammatory bowel disease (IBD). Mesalamine, which is a sulpha-free 5-ASA, is used extensively in the treatment of IBD and is generally considered to be a safe and effective drug in the treatment of ulcerative colitis with headache, drug fever, rash, paradoxical disease exacerbation, pancreatitis, hepatitis, pericarditis, pneumonitis, and nephritis being reported with its use. Up to 45% of patients receiving 5-ASA compounds experience an adverse reaction to some degree.1 Bradycardia has rarely been reported as a side effect of mesalamine use, and to our knowledge there are only four case reports of bradycardia following mesalamine use in the literature. Here, we report a patient who developed symptomatic bradycardia after treatment with mesalamine.

Case report

A 45-year-old woman with diabetes was admitted to our hospital with complaints of bloody diarrhoea and significant weight loss over the past month. There was no significant past or family history of cardiac or gastrointestinal illnesses.

At presentation, heart rate was 110 beats per minute, temperature 36.8°C, blood pressure 120/86 mmHg and respiratory rate 18 cycles per minute. Per abdominal examination was unremarkable except for scar of abdominal hysterectomy. Routine blood work showed her haemoglobin was 13.4 g, erythrocyte sedimentation rate 56, and C-reactive protein 5.29 mg/dL. Stool routine was normal. Stool culture showed no growth. Contrast-enhanced CT abdomen showed mild circumferential rectal wall thickening (maximum thickness 5 mm) with perifocal fat stranding and perifocal lymphadenopathy suggestive of proctitis. A colonoscopy was done which showed ulcerative procto-sigmoiditis (Mayo endoscopic score 3). Colonic mucosal biopsy confirmed active ulcerative colitis, and the patient was initiated on IV hydrocortisone and oral mesalamine. However, within 24 hours of starting mesalamine, the patient complained of giddiness and chest discomfort. An ECG performed showed sinus bradycardia with a heart rate of around 40 beats per minute with no acute myocardial ischemia (Fig 1). Cardiology opinion was sought and work-up for bradycardia was performed. Her 2D echo was normal, as were cardiac enzymes, thyroid function tests and electrolytes including potassium, calcium, magnesium and phosphorus. Since the patient developed bradycardia after initiation of treatment for ulcerative colitis, mesalamine was considered as a probable cause for bradycardia and this was stopped. Her bradycardia resolved within 24 hours of stopping mesalamine and she remained asymptomatic throughout her hospital course (Fig 2). A rechallenge was not attempted due to possible serious cardiac adverse events. She was transitioned to oral steroids and given azathioprine on discharge.

Fig 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 1.

ECG on mesalamine therapy.

Fig 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 2.

ECG after stopping mesalamine therapy.

Discussion

Mesalamine is a sulpha-free 5 ASA preparation that is commonly used in clinical practice with a half-life of about 25 hours. Side effects of mesalamine include headache, arthralgia, nausea, vomiting, drug fever, rash, paradoxical disease exacerbation, pancreatitis, hepatitis, pericarditis, pneumonitis and nephritis. The mechanism of action is by inhibition of the activity of the nuclear factor-kappa B (NF-κB) pathway, inhibition of intestinal epithelial cell injury, inhibition of chemoattractant leukotrienes, and modulation of prostaglandin metabolism.2

Mesalamine-induced sinus bradycardia has been reported in four cases so far.3,4 In one case report, it was postulated to be due to an unrecognised unique predisposing factor like cardiac conduction abnormality unmasked by mesalamine use.2 One other case report postulated a modulating effect on prostaglandin metabolism as the pathologic mechanism of bradycardia.5 Another case report postulated mesalamine-induced myocarditis as the cause for bradycardia. However, there is inadequate evidence to identify the mechanism through which mesalamine causes bradycardia. Mesalamine is the cornerstone of ulcerative colitis treatment. In these patients, one must decide whether to discontinue the medication, reduce the dosage, or continue the same medication in the presence of symptomatic bradycardia. Such decisions are now made without knowledge of pathophysiology or natural history of mesalamine-induced bradycardia. Our case study highlights this gap in knowledge and need for further research into the pathophysiology and prognosis of mesalamine induced bradycardia.

Conclusion

Clinicians should be aware of this rare, albeit serious, adverse effect of mesalamine-induced bradycardia. Although the exact pathogenesis of this adverse effect is not known, further research is required to establish the mechanism, natural history, and prognosis of bradycardia in patients receiving mesalamine.

  • © Royal College of Physicians 2023. All rights reserved.

References

  1. ↵
    1. Lichtenstein GR
    (ed). Medical therapy of ulcerative colitis. Springer; 2014.
  2. ↵
    1. Desreumaux P
    , Ghosh S. Mode of action and delivery of 5-aminosalicylic acid – new evidence. Aliment Pharmacol Ther 2006;24:2–9.
    OpenUrlCrossRef
  3. ↵
    1. Asirvatham S
    , Sebastian C, Thadani U. Severe symptomatic sinus bradycardia associated with mesalamine use. Am J Gastroenterol 1998;93:470–1.
    OpenUrlPubMed
  4. ↵
    1. Barquero-Romero J
    , Arrobas-Vacas J, López-Santamaría JL, López-Santamaría C. [Sinus bradycardia associated with mesalazine]. Med Clin (Barc) 2006;126:639.
    OpenUrlPubMed
  5. ↵
    1. Krzyzak M
    , Gupta A, Antonov E. Mesalamine-associated bradycardia. Cureus 2018;10:e2425.
    OpenUrl
Back to top
Previous articleNext article

Article Tools

Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Drug-induced bradycardia
Devamsh GN, Mallikarjun Patil, Syed Shafiq
Clinical Medicine Mar 2023, 23 (2) 173-174; DOI: 10.7861/clinmed.2022-0431

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Drug-induced bradycardia
Devamsh GN, Mallikarjun Patil, Syed Shafiq
Clinical Medicine Mar 2023, 23 (2) 173-174; DOI: 10.7861/clinmed.2022-0431
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Case report
    • Discussion
    • Conclusion
    • References
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Acute ptotic myelopathy: cervical compressive myelopathy resulting from prolonged head ptosis after alcohol intoxication
  • Pleural-based giant solitary fibrous tumour with associated hypoglycaemia: unusual presentation with pulmonary hypertension in a patient with Doege–Potter syndrome
  • Nitrous oxide misuse: a clue not to be missed in young patients with venous thromboembolism
Show more Lesson of the month

Similar Articles

FAQs

  • Difficulty logging in.

There is currently no login required to access the journals. Please go to the home page and simply click on the edition that you wish to read. If you are still unable to access the content you require, please let us know through the 'Contact us' page.

  • Can't find the CME questionnaire.

The read-only self-assessment questionnaire (SAQ) can be found after the CME section in each edition of Clinical Medicine. RCP members and fellows (using their login details for the main RCP website) are able to access the full SAQ with answers and are awarded 2 CPD points upon successful (8/10) completion from:  https://cme.rcplondon.ac.uk

Navigate this Journal

  • Journal Home
  • Current Issue
  • Ahead of Print
  • Archive

Related Links

  • ClinMed - Home
  • FHJ - Home
clinmedicine Footer Logo
  • Home
  • Journals
  • Contact us
  • Advertise
HighWire Press, Inc.

Follow Us:

  • Follow HighWire Origins on Twitter
  • Visit HighWire Origins on Facebook

Copyright © 2023 by the Royal College of Physicians